How collagen affects metabolism and immunity in pancreatic cancer
Regulation of PDAC metabolism and immunity by collagen and its cleavage products
This study is looking at how the tough tissue around pancreatic cancer affects its growth and the body's immune response, with the goal of finding better ways to treat patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10920390 on NIH RePORTER |
What this research studies
This research investigates the complex interactions between pancreatic ductal adenocarcinoma (PDAC) and its surrounding collagen-rich stroma. It aims to understand how collagen, particularly Type I collagen, influences tumor growth and immune responses. By examining the balance between tumor-promoting and tumor-suppressive effects of the stroma, the study seeks to identify mechanisms that could improve treatment outcomes for patients. The research will utilize clinical data and laboratory techniques to explore how collagen cleavage affects cancer progression and immune evasion.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are undergoing treatment or have had surgical resection.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance treatment effectiveness for pancreatic cancer patients.
How similar studies have performed: Previous research has shown promising results in understanding the role of the tumor microenvironment in cancer progression, indicating that this approach has potential for success.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Karin, Michael — University of California, San Diego
- Study coordinator: Karin, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.